Introduction: Ticagrelor is a first drug of a new chemical class cyclopentyltriazolopyrimidines.
It is an antiplatelet agent with a unique mechanism of action, allowing a direct and reversible …

Dual antiplatelet therapy, composed of aspirin plus a P 2 Y 12‐receptor antagonist, is the
cornerstone of treatment for patients with acute coronary syndrome (ACS). A number of US …

Ticagrelor is a reversible P2Y12 receptor antagonist that is more potent than clopidogrel.
When used in combination with aspirin, it reduces cardiovascular events in patients with …

Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic
cardiac complications in patients with acute coronary syndrome. Treatment guidelines for …

Platelets participate centrally in atherothrombosis, resulting in vessel occlusion and
ischaemia. Consequently, optimisation of antiplatelet regimens has the potential to further …

Cardiovascular (CV) deaths are one of the leading cause of death, both in developed and
developing countries, with acute coronary syndrome (ACS) accounting for about 50% of all …

Acute coronary syndrome (ACS) is a leading cause of myocardial infarction in the world. It is
one of the major cause of mortality in the present lifestyle scenario and a main reason for …

Dual antiplatelet therapy is essential for the management of acute coronary syndrome. In
particular, combination therapy using aspirin with a platelet ADP (ie P2Y12) receptor …

Ticagrelor (AZD6140), a cyclopentyl-triazolo-pyrimidine, is the first orally available
antagonist of the ADP receptor of the P2Y12 subtype. Ticagrelor inhibits platelets in a …

Importance of the field: High platelet reactivity has been linked to recurrent ischemic events
in patients treated with conventional dual antiplatelet therapy, in patients with arterial …